Navigation Links
HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
Date:4/16/2012

CHARLOTTESVILLE, Va., April 16, 2012 /PRNewswire/ -- HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, has been invited to present at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) conference.  The conference will be held April 18-20, 2012 at the Hilton Chicago, 720 South Michigan Avenue in Chicago, Illinois.

(Logo:  http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

The company will occupy booth No. six for recruiting purposes and present two scientific abstracts:

Atheroprone Hemodynamics and Oxidized Phospholipids Enhance Endothelial and Smooth Muscle Inflammatory Signaling

  • Presentation Date and Time: April 18th from 5:30pm to 7:30pm
  • Abstract ID Number: 580
  • Poster Presentation Number: 179
  • Presenter:  Ryan Feaver, Ph.D., HemoShear, Scientific Director

The Thrombotic Potential of the Endothelium Is Regulated by Hemodynamic Flow

  • Presentation Date and Time: April 20th from 8:00am to 10:00am
  • Abstract ID Number: 588
  • Poster Presentation Number: 521
  • Presenter:  Michael Simmers, Ph.D., HemoShear, Scientific Director

HemoShear team members attending the conference include Brett Blackman, Ph. D., co-founder, Chief Scientific Officer; Brian Wamhoff, Ph.D., co-founder, Vice President of Research and Development; Nicole Hastings, Ph.D., Vice President of Operations; Ryan Feaver, Ph.D., Scientific Director; Michael Simmers, Ph.D., Scientific Director.

About HemoShear, LLC

HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development.  Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies.  HemoShear's science leads to new medicines and improves human health.  


'/>"/>
SOURCE HemoShear, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
10. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... Researchers at the ... commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject ... it now. , Diagnostic biomarkers are signposts in the blood, lung fluid or ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... -- The new GEZE SecuLogic access control ... system solution for all door components. It can be ... interface with integration authorization management system, and thus fulfills ... dimensions of the access control and the optimum integration ... considerable freedom of design with regard to the doors. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
Breaking Biology News(10 mins):